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Familial hypercholesterolemia due to heterozygous LDL-receptor mutations is a common 
inborn errors of metabolism. Secondary hypercholesterolemia due to a defect in phytosterol 
metabolism is far less common and may escape diagnosis during the work-up of patients with 
dyslipidemias. Here we report on two sisters with the rare, autosomal recessive condition, 
sitosterolemia. This disease is caused by mutations in a defective ATP-binding cassette sterol 
excretion transporter, leading to highly elevated plant sterol concentrations in tissues and to a 
wide range of symptoms. After a delayed diagnosis, treatment with a diet low in plant lipids 
plus ezetimibe to block the absorption of sterols corrected most of the clinical and biochemical 
signs of the disease. We followed the two patients for over ten years and report their initial 






Elevated cholesterol concentrations are not always identical with familial 
hypercholesterolemia, and sitosterolemia should be included as a treatable differential 
diagnosis. This is especially relevant if family screening does not confirm familial 
hypercholesterolemia in at least one of the parents.  
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Sitosterolemia (MIM #210250) is a rare, autosomal-recessive disease characterized by 
accumulation of plant sterols in blood and tissues (Patel and Salen 2010). Sitosterolemia was 
first described in 1973, when elevated plasma levels of plant sterols (sitosterol, campesterol and 
stigmasterol) were detected in  two sisters of European descent who had extensive tendon 
xanthomas but normal plasma cholesterol levels (Bhattacharyya and Connor 1974). Although 
the exact prevalence of sitosterolemia is not known, it may be underdiagnosed and in fact more 
common than the estimated incidence of 1 in 1,000,000 (Kidambi and Patel 2008; Park et al. 
2014; Yoo 2016). In fact, recent data indicate a prevalence of the disease more than 1 in 
~200,000 individuals among the general population (Tada et al. 2018a). 
Sitosterolemia is caused by mutations in either the ABCG5 or the ABCG8 gene (Berge et al. 
2000; Lee et al. 2001; Lu et al. 2001), two oppositely oriented genes located on chromosome 
2p21 (Patel et al. 1998). Inactivating mutations of both alleles at either the ABCG5 or ABCG8 
locus cause sitosterolemia. A single report of a patient with sitosterolemia who is heterozygous 
for a mutation in both genes has been reported (Tada et al. 2018b). While almost all Asian 
patients carry ABCG5 mutations, Caucasian patients more often present ABCG8 mutations 
(Park et al. 2014; Patel and Salen 2010; Tada et al. 2015; Wang et al. 2004). ABCG5 and ABCG8 
are coding for sterolin 1 and sterolin 2, respectively, which form an obligate heterodimer and 
ATP-binding cassette transporter (Fig. 1) (Berge et al. 2000; Lee et al. 2001; Lu et al. 2001; 
Wang et al. 2004). Loss of function of this transporter leads to increased absorption of all dietary 
sterols and thus to progressive accumulation of sterols. While plasma cholesterol is often 
normal in adult patients with sitosterolemia, pediatric patients can show severe 
hypercholesterolemia (Patel and Salen 2010; Yoo 2016). 
Clinically, sitosterolemia is very heterogeneous with a spectrum that extends from the patients 
being asymptomatic to early lethal cases (Wang et al. 2004; Yoo 2016). Typical manifestations 
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are listed in Table 1. The complete clinical expression of  sitosterolemia may not be known due 
to under-diagnosis (Merkens et al. 1993).  
To diagnose this disorder requires the measurement of plant sterol concentrations in plasma 
using gas chromatography-mass spectrometry (GC-MS) or high pressure liquid 
chromatography (HPLC). Standard enzymatic cholesterol analysis does not distinguish 
between plant sterols and cholesterol and therefore can lead to false high total cholesterol 
concentrations (Patel and Salen 2010; Yoo 2016). Mutation analysis can be made by sequencing 
the ABCG5 and ABCG8 gene (Niu et al. 2010; Yoo 2016).   
Treatment of sitosterolemia aims to lower plasma plant sterols and, if elevated, cholesterol 
concentrations and to prevent complications (Merkens et al. 1993; Yoo 2016). To achieve this, 
a combination therapy is usually needed (Yoo 2016): dietary restriction of both animal- and 
plant-based sterols (Belamarich et al. 1990; Merkens et al. 1993; Parsons et al. 1995); bile acid 
sequestrants, e.g. cholestyramine (Belamarich et al. 1990; Merkens et al. 1993; Parsons et al. 
1995); and ezetimibe to reduce sterol uptake (Lutjohann et al. 2008; Merkens et al. 1993; 
Othman et al. 2015; Salen et al. 2006; Salen et al. 2004). Treatment results in a reduction in 
plasma concentrations of cholesterol and plant sterols and regression of existing xanthomas 
(Merkens et al. 1993; Yoo 2016). Thus, sitosterolemia is a treatable condition, especially when 
diagnosed and treated early, which underlines the importance of correct diagnosis and 
management of sitosterolemia (Yoo 2016).  
Here we report on two patients with sitosterolemia who were initially not recognized to have 




Case Reports  
Patient 1, first child of non-consanguineous Bosnian parents, was referred to our unit at age 8.5 
years after her parents gave a one year history of her developing bluish soft swellings on the 
extensor surfaces of both her knees and elbows. On physical examination, she was found to 
also have similar lesions on the buttocks and the Achilles tendons. Previously, one of the lesions 
had been biopsied and the diagnosis of “xanthoma disseminatum” was made. Her fasting blood 
total and LDL-cholesterol levels were 12.1 mmol/L and 10.2 mmol/L, respectively. Treatment 
with statins did not significantly lower her LDL-cholesterol and the patient proceeded to 
develop xanthelasmas. Both of her patents had cholesterol levels that were only slightly 
elevated above the upper limit of normal, already raising suspicion about the possibility of a 
LDL-receptor defect. Her younger sister was also tested and had a total cholesterol of 7.3 
mmol/L and LDL-cholesterol of 5.2 mmol/L. The family history beyond that was uneventful.   
Sequencing of the coding exons of the genes encoding for the LDL-receptor and 
apolipoprotein B in all family members did not reveal mutations. Finally, after 2.5 years, the 
plasma phytosterols were measured by gas chromatography-mass spectrometry (GC-MS) and 
found to be very elevated (sitosterol 555 µmol/L, ref. 0.6 - 14.88; campesterol 353 µmol/L, ref. 
0.52 - 17.65) (Fig. 2). Genomic DNA from peripheral white blood cells was used for sequencing 
all exons of ABCG5 and ABCG8 (performed at University of Texas Southwestern Medical 
Center) (Hubacek et al. 2001). This revealed that both patients were homozygous for a stop 
mutation at position 446 of ABCG5 (p.Arg446*) and that both parents were carriers of the 
nonsense mutation.  
When diet therapy for about 6 months plus colestid treatment for about 2 months did not lead 
to a reduction in plasma sterol levels, ezetimibe was added to the medical regimen. Treatment 
with ezetimibe led to a significant decrease of total and LDL-cholesterol levels, as well as to a 
decrease in concentrations of phytosterols (Fig. 2). In patient 1, treatment with ezetimibe lead 
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to an initial normalization of total and LDL-cholesterol but levels increased later slightly above 
the reference ranges, while in patient 2 the concentrations of total and LDL-cholesterol 
remained normalized until the end of the observation period (Table 2 and Fig. 2). During 
treatment, xanthoma in patient 1 disappeared after several years with minimal bluish skin 
discoloration remaining in the respective areas of knees and elbows. 
To investigate for known complications of sitosterolemia, platelet aggregation tests, thrombo-
FACS, platelet electron microscopy, ferritin, free hemoglobin (Hb), and Hb-carbonmonoxide 
(CO) were analysed and found normal in both patients. Specifically, there was no evidence for 
the presence of hemolysis, abnormally shaped erythrocytes (stomatocytes) or thrombocytes 
(macrothrombocytopenia). Platelet aggregation was normal, as was expression of platelet 
surface proteins GPIb, IIb, and IIIa. All examined markers could be stimulated by thrombin. 
In patient 1, echocardiography at 12.8 years of age showed hyperechogenic and thickened areas 
at the base of the mitral and tricuspid valves. One year later, a calcification had developed on 
the sinotubular junction, but without causing stenosis. These findings remained unchanged until 
the end of the observation period. When ECG showed signs of a disturbed repolarization, a CT 
angiography was done to exclude coronary artery involvement. This revealed normal coronary 
arteries but calcified plaques in the left ventricular outflow tract and in the wall of the ascending 
aorta (Fig. 3). Patient 2 showed no cardiac involvement but additional morbidities including 
infantile epilepsy and mixed hyperandrogenemia (acne, mild hirsutism and oligomenorrhoea).  
Parents of the reported patients provided their consent to publication of this report.  
 
Discussion  
Sitosterolemia is a rare and probably underdiagnosed autosomal recessive disorder of lipid 
metabolism. The clinical presentation is variable, making early diagnosis challenging. Since the 
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condition can lead to development of premature coronary atherosclerosis, which can be 
prevented by treatment, it is important that the disease be diagnosed early. Here we review the 
clinical presentation and successful management of two sisters with the disorder. In the index 
patient, the diagnosis of the disease was delayed by more than two years. After consultation 
with several specialities, the patient was assumed to have familial hypercholesterolemia (FH) 
based on an elevated LDL-cholesterol levels. However, treatment with statins alone failed, 
which is typical for sitosterolemia patients and a useful clue to the diagnosis. The initial 
misdiagnosis is likely the result of sitosterolemia being a rare disease, with less than 100 cases 
described to date (Bazerbachi et al. 2017). Besides several case reports, the largest case series 
reports 13 patients from 8 independent families, who were all treated at a single institution 
(Wang et al. 2014).  
Diagnosis of sitosterolemia requires a high level of awareness, since the standard lipid profiles 
provide no specific hints. Rather, specific phytosterol analysis must be requested (Bazerbachi 
et al. 2017). Another clue is that parents are normocholesterolemic, as it was in principle the 
case in the reported family with only slight cholesterol elevations in the parents. In case of 
absent hypercholesterolemia in the parents of a patient, and if xanthoma are present in typical 
body areas, physicians should include sitosterolemia in the differential diagnosis of elevated 
cholesterol concentrations. Confirmation of the disease may include analysis of ABCG5 and 
ABCG8 genes but mutation analysis is not required to make the diagnosis. Both our patients 
were homozygous for a previously reported stop mutation (c.1336C>T, p.Arg446*) in the 
ABCG5 gene (Mannucci et al. 2007). This mutation was found in at least 19 patients from 
different origins: Iranian (Mannucci et al. 2007), Japanese (Tada et al. 2015; Togo et al. 2009), 
Chinese (Niu et al. 2010), Romanian (Rios et al. 2010), Korean (Park et al. 2014), Turkish (Li 
et al. 2016) and Pakistani (Bazerbachi et al. 2017), plus further patients (Fang et al. 2018; Kratz 
et al. 2007; Wang et al. 2014). Our patients are of Bosnian origin and therefore serve as 
9 
 
examples for genetic heterogeneity at both loci. Previously, Asian patients more often carried 
ABCG5 mutations, while Caucasian patients were more frequently affected by mutations in 
ABCG8 (Berge et al. 2000; Kidambi and Patel 2008; Lu et al. 2001; Patel and Salen 2010). 
The importance of early diagnosis and initiation of treatment is underlined by the different 
clinical and biochemical course in our patients: while patient 1 presented with multiple clinical 
signs including cardiac calcifications, patient 2 was asymptomatic. Also, maximum 
concentrations of cholesterol and of phytosterols in patient 1 were noticeably higher than in 
patient 2. While there are no apparent differences between patients with mutations in ABCG5 
or ABCG8 (Lee et al. 2001; Lu et al. 2001), there is considerable heterogeneity in the clinical 
and biochemical phenotypes of patients even with identical genotypes (Hu et al. 2014; 
Mannucci et al. 2007; Park et al. 2014; Wang et al. 2004). The cause of this variability is not 
known, but time of diagnosis and start of treatment may contribute. Additional factors may 
include NPC1L1 polymorphisms leading to reduced sterol absorption and LDL-cholesterol 
levels (Cohen et al. 2006; Hu et al. 2014; Kidambi and Patel 2008; Tang et al. 2009; Teslovich 
et al. 2010), variations in other lipid-related genes influencing cholesterol absorption or other 
pathways (Teslovich et al. 2010), and differences in dietary sterol intake (Hu et al. 2014), the 
latter especially in infants consuming different diets (Merkens et al. 1993). 
Management of our patients included cardiac investigations, regular monitoring of lipid and 
sterol profiles, and liver transaminases alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST), alkaline phosphatase (ALP) and gamma glutamyl transferase (GGT) 
to rule out liver involvement (Bazerbachi et al. 2017). Hematological investigations showed no 
stomatocytes, normal thrombocyte morphology and function, and no disturbance of hemostasis 
(Niu et al. 2010; Patel and Salen 2010; Wang et al. 2011; Wang et al. 2014; Yoo 2016). 
Recently, it was suggested that “elevation of LDL-cholesterol seems to be the major cause of 
development of atherosclerosis and not the elevation of sitosterols” (Tada et al. 2018a) 
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rendering normalization of the cholesterol concentrations, as achieved in both patients, the 
primary treatment target. 
Infantile epilepsy, present in patient 2, has been reported before in a single Chinese 
sitosterolemia patient (Hu et al. 2014), but a causal relationship is unclear. As well, 
sitosterolemia may have contributed to altered androgens and mixed hyperandrogenemia since 
plant sterols can serve as precursors for steroid hormones (Malaviya and Gomes 2008). 
However, the effect of phytosterols on the endocrine system is not completely understood. It is 
known that absorbed plant sterols mainly accumulate in the liver, gonads and adrenal glands 
indicating a high affinity to steroid-synthesizing tissues (Moghadasian 2000). Further 
supporting a role of plant sterols, phytosterol-enriched margarines led to a slight increase in 
testosterone in 10 women (Ros et al. 2007).  
In summary, elevated cholesterol concentrations are not always identical with FH, and 
sitosterolemia should be included as a treatable differential diagnosis. This is especially relevant 
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Legends to tables 
Table 1: Possible clinical presentations of sitosterolemia 
Table 2: Basic clinical and biochemical data of study patients  
 
Legends to figures 
Legend Figure 1: Model for absorption and secretion of cholesterol and plant sterols: 
Physiologically, the ABCG5/G8 transporter pumps absorbed nutrition sterols (absorbed 
through the Niemann-Pick-C1-like 1, short NPC1L1) back into the intestinal lumen or into the 
bile, with a preference for non-cholesterol sterols, if they are present. It occurs in the apical 
membrane of small intestine enterocytes and hepatocytes.  
BA: bile acids, PL: phospholipids, BSEP: bile salt export pump, BDR3: multiple drug resistance 
protein 3, NTCP: sodium/taurocholate co-transporter.  
 
Legend Figure 2: Lipid levels, symptoms and treatments of both patients during the 
observation period 
 
Legend Figure 3: Clinical pictures and CT scan of patient 1. Xanthelasma at age 11.2 (A), 11.9 
(B) and 13.3 years (C). Xanthomata at age 8.8 (D), 11.2 (E) and 13.3 years (F). CT scan with 
cardiac calcifications at age 13.5, arrows indicate site of calcifications (G, H).   
 
 
 
